NasdaqGS:AGIOBiotechs
Does UAE Thalassemia Approval for PYRUKYND Reframe the Bull Case for Agios Pharmaceuticals (AGIO)?
In March 2026, Agios Pharmaceuticals announced that the Emirates Drug Establishment approved PYRUKYND (mitapivat) as the only authorized treatment in the UAE for adult patients with both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, expanding its reach in the Gulf region via its NewBridge Pharmaceuticals partnership.
This approval deepens Agios’s footprint in rare hematologic diseases across the Gulf Cooperation Council, reinforcing the importance of...